Actelion Raises Forecast Amid Higher Sales of New Medicine

Updated on

Actelion Ltd. boosted its earnings forecast and Chief Executive Officer Jean-Paul Clozel said he isn’t interested in selling the Swiss drugmaker following a newspaper report that it spurned an advance from Shire Plc.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.